| Total population (n = 2247) | Lower GA (≤ 14.4%, n = 1133) | Higher GA (> 14.4%, n = 1114) | P value |
---|---|---|---|---|
Medication at admission, n (%) | ||||
 ACEI/ARB | 500 (22.3) | 246 (21.7) | 254 (22.8) | 0.535 |
 DAPT | 677 (30.1) | 348 (30.7) | 329 (29.5) | 0.542 |
 Aspirin | 1192 (53.0) | 598 (52.8) | 594 (53.3) | 0.797 |
 P2Y12 inhibitors | 718 (32.0) | 371 (32.7) | 347 (31.1) | 0.417 |
 β-Blocker | 496 (22.1) | 251 (22.2) | 245 (22.0) | 0.927 |
 Statins | 691 (30.8) | 370 (32.7) | 321 (28.8) | 0.048 |
 OHA | 400 (17.8) | 56 (4.9) | 344 (30.9) |  < 0.001 |
 Insulin | 218 (9.7) | 13 (1.1) | 205 (18.4) |  < 0.001 |
Medication at discharge, n (%) | ||||
 ACEI/ARB | 1558 (69.3) | 758 (66.9) | 800 (71.8) | 0.012 |
 DAPT | 2245 (99.9) | 1133(100.0) | 1112 (99.8) | 0.154 |
 Aspirin | 2246 (100.0) | 1133 (100.0) | 1113(99.9) | 0.313 |
 P2Y12 inhibitors | 2247 (100.0) | 1133 (100.0) | 1114 (100.0) | – |
 β-Blocker | 2045 (91.0) | 1024 (90.4) | 1021 (91.7) | 0.292 |
 Statins | 2195 (97.7) | 1101 (97.2) | 1094 (98.2) | 0.105 |
 OHA | 396 (17.6) | 56 (4.9) | 340 (30.5) |  < 0.001 |
 Insulin | 211 (9.4) | 12 (1.1) | 199 (17.9) |  < 0.001 |
Angiographic data, n (%) | ||||
 LM lesion | 102 (4.5) | 45 (4.0) | 57 (5.1) | 0.192 |
 Multi-vessel lesion | 1498 (66.7) | 655 (57.8) | 843 (75.7) | < 0.001 |
 In-stent restenosis | 124 (5.5) | 47 (4.1) | 77 (6.9) | 0.004 |
 Chronic total occlusion lesion | 295 (13.1) | 136 (12.0) | 159 (14.3) | 0.111 |
 SYNTAX score | 11.0 ± 5.4 | 10.0 ± 5.1 | 12.0 ± 5.5 | < 0.001 |
Procedural information | ||||
 Target vessel territory, n (%) | ||||
  LM | 60 (2.7) | 31 (2.7) | 29 (2.6) | 0.845 |
  LAD | 1464 (65.2) | 738 (65.1) | 726 (65.2) | 0.987 |
  LCX | 784 (34.9) | 364 (32.1) | 420 (37.7) | 0.006 |
  RCA | 952 (42.4) | 434 (38.3) | 518 (46.5) | < 0.001 |
  Complete revascularization, n (%) | 1323 (58.9) | 746 (65.8) | 577 (51.8) | < 0.001 |
  Number of DES | 2.0 ± 1.3 | 1.9 ± 1.3 | 2.0 ± 1.3 | 0.022 |